IL24 and neoplasm: This is clinically relevant, since administering a sufficient titer of CTV-m7 can easily be achieved based on its cancer-selective replication at the tumor site, which is not achievable with a non-replicating Ad.mda-7, and activity can be further potentiated by using BH3 mimetics, e.g., BI-97D6.